NCT05543330View on ClinicalTrials.gov

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

October 15, 2026

Conditions
Malignant Pleural EffusionsNSCLC Stage IV
Interventions
DRUG

M701 pleural infusion

M701 pleural infusion on Days 1,4,7 and 10.

PROCEDURE

Pleural drainage

Pleural effusion drainage via Ultra-sound guidance on Day 1.

DRUG

Cisplatin pleural infusion

Cisplatin pleural infusion (30-50mg/m2) on Day 1.

Trial Locations (1)

310022

RECRUITING

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

All Listed Sponsors
lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY